Anti-IL13 Recombinant Immunotoxin Cintredekin Besudotox (IL13-PE38QQR) (CAT#: BioBet-IT001Z) Datasheet

Target
IL13
IT Type
Ligand-based IT
Description
Cintredekin besudotox has been developed as a specific tumor targeting agent that can be directly applied to brain tissue at risk of residual infiltrating glioblastoma (GBM) after tumor resection through positive pressure convection enhanced delivery (CED). Cintredekin besudotox is made of human protein Interleukin 13 (IL13) linked to the bacterial toxin Pseudomonas exotoxin (PE). IL13 partially binds to receptors on the tumor.
Indication
Brain cancer
Classification
Immuntoxin; biobetter
Construction
IL13-PE38QQR
Accession Number
DB05305
CAS number
Not Available
UNII
ZL04JX89M7

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL13
Full Name
Interleukin 13
Background
This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. [provided by RefSeq, Jul 2008]
Alternative Names
Interleukin 13
Gene ID
Entrez Gene: 3596
UniProt ID
UniProtKB: P35225
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Species Reactivity
Human
Antibody Indication
Brain cancer
LIgand
IL13 receptor
Toxic Moiety
PE38QQR
Organism
Pseudomonas aeruginosa
Family
Pseudomonas exotoxin A
Molecular Mass
38 kDa
Toxic MOA
PE38 is a 38 kDa truncated form of Pseudomonas exotoxin (PE) containing amino acids 253–364 and 381–613. Pseudomonas exotoxin (or exotoxin A) is an exotoxin produced by Pseudomonas aeruginosa. Vibrio cholerae produces a similar protein called Cholix toxin (Q5EK40). It inhibits elongation factor 2. This is achieved by ADP ribosylation of EF2 using NAD +. This then causes the extension of the polypeptide to stop. This mechanism is similar to diphtheria toxin.

Recombinant chimeric protein with strong anti-tumor activity. Cintredekin besudotox consists of the pleiotropic immunomodulatory cytokine interleukin 13 (IL13), which is linked to the mutant form of Pseudomonas exotoxin A. The drug targets and kills tumor cells that express IL13 receptor (IL13R). IL13 is partially attached to IL13R on the tumor cell membrane, promoting the entry of exotoxin. Exotoxin induces caspase-mediated apoptosis of tumor cells in part through mechanisms involving mitochondrial damage. It also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor 2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.

Brain cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK